Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
CollaGenex Pharmaceuticals Announces Results of Phase 4 Clinical Study Showing Oracea Equally Effective as 100 mg Doxycycline in Treatment of Rosacea
February 2nd, 2008
CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) announced results of a Phase 4 dose-comparison study designed to evaluate the safety and efficacy of Oracea(R) once daily versus doxycycline 100 mg once daily for the treatment of rosacea. A presentation of the results was made yesterday by James Q. Del Rosso, D.O., Clinical Assistant Professor, Department of Dermatology at the University of Nevada, School of Medicine, at the 7th Annual Caribbean Dermatology Symposium. Oracea is a patented, delayed release formulation of doxycycline, 40 mg, that is the only FDA-approved treatment for the papules and pustules associated with rosacea. Doxycycline at much higher doses is often...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2008-02-02)
|
